Related Experiment Videos
Antimicrobial peptides: therapeutic potential
Lijuan Zhang1, Timothy J Falla
1Helix Biomedix, Inc., Bothell, WA 98021, USA. lzhang@helixbiomedix.com
Expert Opinion on Pharmacotherapy
|March 25, 2006
Summary
Cationic host defence peptides are key to innate immunity and offer diverse therapeutic benefits beyond antimicrobial activity. Ongoing research and reduced costs are driving their advancement into clinical trials for various diseases.
Area of Science:
- Immunology
- Biochemistry
- Pharmacology
Background:
- Cationic host defence peptides (CHDPs) are crucial components of the innate immune system in diverse organisms.
- In humans, CHDPs exhibit direct antimicrobial effects and possess non-antimicrobial bioactivities involved in defense, inflammation, and wound healing.
Purpose of the Study:
- To review the current status and future prospects of CHDPs as therapeutics.
- To highlight the reasons for renewed interest and ongoing clinical development of CHDPs.
Main Methods:
- Literature review of existing research on CHDPs.
- Analysis of clinical trial programs and therapeutic areas.
Main Results:
- CHDPs demonstrate a broad spectrum of bioactivities beyond antimicrobial action.
- Clinical programs are active in infection, dermatology, cancer, and inflammation.
Conclusions:
- Despite past market failures, CHDPs show increasing promise as therapeutics due to reduced manufacturing costs and newly identified bioactivities.
- The probability of clinical success for CHDP-based therapies is rising across a wider range of indications.